cyc 202 has been researched along with Parkinsonian Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, Y; Ge, R; Han, J; Hou, Y; Wang, H; Xu, J | 1 |
| Döbrössy, M; Nikkhah, G; Surchev, L; Tomov, N; Wiedenmann, C | 1 |
| Guan, Q; He, Y; Jin, L; Liu, X; Zhao, L | 1 |
3 other study(ies) available for cyc 202 and Parkinsonian Disorders
| Article | Year |
|---|---|
Protective effect of roscovitine against rotenone-induced parkinsonism.
Topics: Animals; Antiparkinson Agents; Brain; Cyclin-Dependent Kinases; E2F1 Transcription Factor; Mice, Inbred C57BL; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Purines; Random Allocation; Retinoblastoma Protein; Roscovitine; Rotenone | 2018 |
Roscovitine, an experimental CDK5 inhibitor, causes delayed suppression of microglial, but not astroglial recruitment around intracerebral dopaminergic grafts.
Topics: Animals; Astrocytes; Brain; Brain Tissue Transplantation; Cyclin-Dependent Kinase 5; Male; Microglia; Neuroprotective Agents; Parkinsonian Disorders; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Roscovitine | 2019 |
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Kinase Inhibitors; Purines; Random Allocation; Rats; Rats, Sprague-Dawley; Roscovitine; Severity of Illness Index; Treatment Outcome | 2010 |